MyFinsight
Home
Blog
About
Cash and cash
equivalents
$18,603,899
(22.62%↑ Y/Y)
Investment in preferred
stock qcls - current
$18,225,000
Marketable equity
securities
$254,010
(-30.66%↓ Y/Y)
Dividends receivable
$240,766
Prepaid expenses and
other current assets
$96,879
(-56.70%↓ Y/Y)
Warrant assets qcls - non
current
$8,845,000
(55.15%↑ Y/Y)
Warrant assets femasys
$480,000
(-84.32%↓ Y/Y)
Other assets
$7,688
(0.00%↑ Y/Y)
Total current assets
$37,420,554
(67.24%↑ Y/Y)
Total other assets
$9,332,688
(-71.54%↓ Y/Y)
Total assets
$46,753,242
(-15.25%↓ Y/Y)
Total liabilities,
temporary equity and...
$46,753,242
(-15.25%↓ Y/Y)
Total stockholders
equity
$33,294,926
(-35.84%↓ Y/Y)
Total liabilities
$11,772,424
(259.21%↑ Y/Y)
Total temporary
equity
$1,685,892
Accumulated deficit
-$104,393,614
(-22.86%↓ Y/Y)
Treasury stock, at cost,
15,270,066 and 14,876,316...
$45,009,541
(0.90%↑ Y/Y)
Accumulated other
comprehensive loss
-$20,796
(12.87%↑ Y/Y)
Additional paid-in capital
$182,716,275
(0.68%↑ Y/Y)
Total other
liabilities
$10,946,000
(2915.43%↑ Y/Y)
Total current
liabilities
$826,424
(-71.64%↓ Y/Y)
Convertible preferred
stock-Series CPreferred...
$1,268,892
Contingently redeemable
warrants
$417,000
Common stock,
authorized 200,000,000...
$2,602
(20.07%↑ Y/Y)
Warrant liability
$10,068,000
(2878.70%↑ Y/Y)
Derivative liability
$878,000
Accrued expenses
$522,831
(-79.21%↓ Y/Y)
Accounts payable
$271,102
(-32.09%↓ Y/Y)
Accrued series c
dividends
$32,491
Back
Back
Balance Sheet
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
source: myfinsight.com